{"id":"W4391544195","doi":"10.1016/s2213-8587(23)00356-x","title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Boehringer Ingelheim","keywords":"Medicine; Placebo; Agonist; Glucagon-like peptide 1 receptor; Liraglutide; Glucagon-like peptide-1; Double blind; Internal medicine; Diabetes mellitus; Pharmacology; Endocrinology; Type 2 diabetes; Receptor; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002742454,0.003980175,0.006688937,0.0008278532,0.0005986331,0.001898236,0.001517856,0.003705737,0.01103399],"category_scores_gemma":[0.002634686,0.001449674,0.003501112,0.0007213297,0.001913782,0.002210632,0.0006811279,0.004717259,0.00181358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001023981,"about_ca_system_score_gemma":0.001358009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001367125,"about_ca_topic_score_gemma":0.002686388,"domain_scores_codex":[0.9990206,0.0004427386,0.00005759422,0.0002313379,0.00007739654,0.0001702842],"domain_scores_gemma":[0.9991517,0.0002900918,0.0001681364,0.00008490896,0.00005511286,0.0002499012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9923652,0.001508037,0.0000964968,0.0005146194,0.000635852,0.00002382593,0.00002454522,0.0001126562,0.0011347,0.00007404278,0.0004463965,0.003063544],"study_design_scores_gemma":[0.9920684,0.007157231,0.0001886401,0.00001543736,0.0001791136,0.000009790559,0.000007340598,0.00007832346,0.00006831865,0.00006311901,0.000156834,0.000007348618],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9601758,0.01437681,0.002757958,0.002593703,0.003509275,0.008663105,0.003575261,0.0005081729,0.003839917],"genre_scores_gemma":[0.9496268,0.00985973,0.004925865,0.004477058,0.001754081,0.01460433,0.002908584,0.000154644,0.01168893],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01103399,"threshold_uncertainty_score":0.03691232,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05994524410212917,"score_gpt":0.343542484035551,"score_spread":0.2835972399334218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}